{'fraction_non_alphanumeric': 0.03330068560235064, 'fraction_numerical': 0.04211557296767875, 'mean_word_length': 4.536585365853658, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
EP1093 Comparison of the effects of vaginal honey jelly with vaginal lubricant gel on atrophic vaginitis symptoms and quality of life in post-menopausal women with endometrial cancer

Introduction/Background General health and welfare of middle-aged women has become a major public health concern around the world. More than 80% of women experience physical or mental disorder symptoms during their menopausal years, which decrease the quality of their life. To compare to the effect of vaginal honey jelly with vaginal lubricant Gel as an alternative treatment for vaginal atrophy and increasing the quality of life in post-menopausal women with endometrial cancer who have limitation for estrogen use. Methodology This is a clinical trial study on 62 women with endometrial cancer referred to the Kosar Hospital in orumiyeh, Iran due to post-menopausal symptoms. The data were collected using a Vulvovaginal Symptom and a Quality of Life Questionnaire (VSQ) and MENQOL questionnaire. At the beginning of the study, patients were taught how to use vaginal lubricant and honey gel. The intervention period was 2 months and the collected data were analyzed using SPSS23 software. Results The mean age in the study group was 55.09 ± 2.25 years and 59.67 ± 1.59 years in the control group. The mean of atrophic vaginitis score before the intervention was 4.58 ± 0.83 in the study group and 2.16 ± 0.55 in the control group. (P=0.02), that after using the medication changed to 3.45 ± 0.62 in study group and 1.96 ± 0.47 in the control group (P=0.07). Mean score of quality of life before intervention in the study group and control group was 29.64 ± 3.93 and 21.29 ± 3.83 respectively (P=0.24), which decreased to 26.35 ± 3.71 and 17.09 ± 3.43. Conclusion The present study showed that vaginal honey jelly can be an appropriate alternative for vaginal atrophy, sexual problems and improving the quality of life in postmenopausal women with endometrial cancer who cannot use estrogen and other hormonal medications. Disclosure Nothing to disclose